-+ 0.00%
-+ 0.00%
-+ 0.00%

AMGEN - PHASE 3 DELLPHI-305 STUDY DELIVERS SIGNIFICANT OVERALL SURVIVAL BENEFIT VERSUS DURVALUMAB ALONE

Reuters·09/08/2026 13:01:15

Please log in to view news